Polysomnographic and pharmacokinetic findings in levodopa-induced augmentation of restless legs syndrome

Movement Disorders

Volumn 21, Issue 2, 2006, Pages 254-258

  Vetrugno, Robert ^a   Contin, Manuela ^a   Baruzzi, Agostino ^a   Provini, Federica ^a   Plazzi, Giuseppe ^a   Montagna, Pasquale ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Augmentation; Levodopa; Pharmacokinetic; Polysomnography; Restless legs syndrome

Indexed keywords

AMITRIPTYLINE; BACLOFEN; BENSERAZIDE PLUS LEVODOPA; BUPRENORPHINE; CARBAMAZEPINE; CLONAZEPAM; LEVODOPA; TRAMADOL;

AGED; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DYSESTHESIA; FEMALE; HUMAN; HYPERACTIVITY; INFANTILE SPASM; LEG PAIN; MOTOR UNIT POTENTIAL; PATHOGENESIS; POLYSOMNOGRAPHY; PRIORITY JOURNAL; RATING SCALE; RESTLESS LEGS SYNDROME; TREATMENT DURATION;

AGED; ANTIPARKINSON AGENTS; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEVODOPA; METABOLIC CLEARANCE RATE; POLYSOMNOGRAPHY; RESTLESS LEGS SYNDROME; SPASM;

EID: 33644933153     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20677     Document Type: Article

References (14)

1. Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4: 101-119.
2. Hening W, Allen R, Earley C, et al. The treatment of restless legs syndrome and periodic limb movement disorder: an American Academy of Sleep Medicine review. Sleep 1999;22:970-999.
3. Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-213.
4. Collado-Seidel V, Kazenwadel J, Wetter TC, et al. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms. Neurology 1999;52:285-290.
5. Comella CL. Restless legs syndrome: treatment with dopaminergic drugs. Neurology 2002;58:S87-S92.
6. Ondo W, Romanyshyn J, Dat Vuong K, Laj D. Long-term treatment of restless legs syndrome with dopamine agonists. Arch Neurol 2004;61:1393-1397.
7. Baruzzi A, Contin M, Riva R, Albani F. Simple and rapid micro-method for the determination of levodopa and 3-O-methyldopa in human plasma by high-performance liquid chromatography with coulometric detection. J Chromatogr 1986;375:165-169.
8. Contin M, Riva R, Martinelli P, et al, Levodopa therapy monitoring in patients with Parkinson's disease: a kinetic-dynamic approach. Ther Drug Monit 2001;23:621-629.
9. Vetrugno R, Plazzi G, Provini F, et al. Excessive fragmentary hypnic myoclonus: clinical and neurophysiological findings. Sleep Med 2002;3:73-76.
10. Contin M, Riva R, Martinelli P, et al. Response to a standard oral levodopa test in parkinsonian patients with and without motor fluctuation. Clin Neuropharmacol 1990;13:19-28.
11. Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999;6:1-21.
12. Fabrini G, Juncos J, Mouradian MM, Serrati C, Chase TN. Levodopa pharmacokinetic mechanisms and motor fluctuations in Parkinson's disease. Ann Neurol 1987;21:370-376.
13. Obeso JA, Rodriguez-Oroz MC, Rodriguez M, et al. Pathophysiology of the basal ganglia in PD. Trends Neurosci 2000;23:8-19.
14. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005;57:17-26.